Testing Safety and Feasibility of Bilateral Middle Meningeal Artery Embolization with Onyx for Adults with Difficult-to-Treat Chronic Migraine

What this Trial Is About

Researchers are evaluating the safety and feasibility of embolizing the middle meningeal arteries MMA using a product called Onyx for patients with refractory chronic migraine. This procedure is not currently approved for migraines but is used for subdural hematomas. The study aims to reduce migraine-causing substances in the brains bloodstream by blocking these arteries. The supplies are provided by Medtronic, and the study is sponsored by Johns Hopkins University. Participants will undergo a procedure called bilateral embolization of the middle meningeal arteries with Onyx. After the procedure, participants will be followed for about 6 months, with the total study participation lasting around 8 months. During this time, participants will continue their regular migraine medications and keep a daily headache diary. Several clinic visits will be scheduled, and blood samples will be collected for research purposes. Throughout the study, participants will attend multiple clinic visits for assessments and provide blood samples. They will also maintain a daily headache diary to track migraine symptoms. The primary outcome measured is the number of specific adverse events related to the procedure within 30 days after embolization. Safety and feasibility will be carefully monitored during the follow-up period to understand the procedures impact on refractory chronic migraine.

Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine